Sanpower Group, a China conglomerate, paid $820 million to acquire Dendreon, which makes Provenge, the world’s first immunotherapy, from Valeant Pharma . Approved as a treatment for prostate cancer in 2010, Dendreon never lived up to expectations because it combined high cost, limited insurance approvals and mediocre improvement over competitors.